Shire casts off non-core drugs for $213M

UK-based Shire Pharmaceuticals is selling a block of medicines to Almirall of Spain for $213 million. The remedies--deemed "non-core products"--include two skin treatments, Solaraze and Vaniqa. Company officials say the move will let Shire focus on its core therapeutic areas: attention deficit disorder, gastrointestinal and renal disease, and genetic therapies.

The company also wants to expand its international reach and develop a new specialty in regenerative medicine. Recently Shire licensed the anti-scarring remedy Juvista from Renovo, in its first foray into the regenerative arena.

- see the release from Shire
- check out this article for more

Related Articles:
Shire to Massachusetts: Pass incentive bill now. Report
FDA signals a quick approval for Shire's ADHD drug. Report
Shire snares New River Pharma in $2.6B buyout. Report
Shire gambit aimed at delaying generic Adderall XR. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.